Gastroesophageal Cancer
Gastroesophageal Cancer
Advertisement
Emily MenendezGastroesophageal Cancer | July 3, 2024
Interleukins can aid in the development of a tumor-directed immune response to improve immunotherapy.
Read More
David H. Ilson, MD, PhDGastric Cancer | June 24, 2024
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Emily MenendezGastroesophageal Cancer | July 15, 2024
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
Emily MenendezGastroesophageal Cancer | June 13, 2024
qFME with oral administration of bevacizumab-800CW and cetuximab-800CW is feasible, and can shorten procedure time.
Cathy Eng, MD, FACP, FASCOGastroesophageal Cancer | June 11, 2024
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
GI Oncology Now EditorsAdvancements in Oncology | June 6, 2024
The trio pondered the evolving landscape of upper GI cancer treatments, particularly in localized and advanced stages.
Emily MenendezGastric Cancer | June 5, 2024
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Filippo Pietrantonio, MDGastric Cancer | June 6, 2024
Drs. Filippo Pietrantonio and Nataliya Uboha break down the results of the phase 3 ARMANI trial.
Katy MarshallGastric Cancer | June 18, 2024
The primary end point of the analysis was OS, and secondary end points included PFS and ORR.
Emily MenendezGastroesophageal Cancer | June 18, 2024
Patients with mPR experienced improved PFS and OS with pembrolizumab plus chemotherapy over placebo plus chemotherapy.
Zev Wainberg, MD, MScASCO 2024: Focus on GI Oncology | May 28, 2024
Drs. Wainberg and Uboha highlight exciting developments set to occur at the ASCO Meeting, including ESOPEC and ARC-9.
Emily MenendezGastric Cancer | June 18, 2024
RELATIVITY-060 investigated the efficacy of first-line relatlimab and nivolumab with chemotherapy for gastric or GEJ cancers.
Zev Wainberg, MD, MScGastric Cancer | May 22, 2024
Drs. Wainberg and Uboha discuss updated results from the FIGHT trial, noting improved OS in gastric cancer/GEJ cancer.
Katy MarshallGastroesophageal Cancer | May 20, 2024
Capecitabine was compared with XELOX and fluorouracil plus cisplatin.
Sunnie Kim, MDGastroesophageal Cancer | May 20, 2024
Dr. Kim provides an overview of the FDA approval of tislelizumab for the treatment of advanced, metastatic esophageal cancer.
Nilay Sethi, MD, PhDGastric Cancer | May 13, 2024
Dr. Sethi continues his comments on NER deficiency in gastric cancer cell lines in response to cisplatin treatment.
Nilay Sethi, MD, PhDGastric Cancer | May 13, 2024
Dr. Sethi discusses homologous recombination and nucleotide excision repair pathways in DNA repair for cancers.
Matthew Strickland, MDGastroesophageal Cancer | May 8, 2024
Matthew Strickland, MD, discusses the current management of defective mismatch repair in gastroesophageal adenocarcinoma.
Katy MarshallGastroesophageal Cancer | May 8, 2024
The effects of primary tumor and LN volume on clinical outcomes in ESCC following neoadjuvant CCRT and surgery are unknown.
Jordi Rodón Ahnert, MD, PhDGastric Cancer | May 7, 2024
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Advertisement
Advertisement
Advertisement
Latest News

July 16, 2024